Heterogeneous planning for homogeneous protocols.
Clinical trials often require homogeneous treatment plans. Many institutions, however, have begun using heterogeneous plans. Is it possible to satisfy the requirements of such a protocol while achieving the superior accuracy of heterogeneous treatment planning? At the University of Texas M. D. Anderson Cancer Center, we currently use conformal treatment planning with heterogeneities for thoracic cancers. This paper describes a procedure that has been developed to satisfy the requirements of a homogeneous protocol, such as RTOG 98-01 (A Phase III Study of Amifostine mucosal protection), while maintaining accuracy in treatment planning.
Brooks
Chris
C
Radiation Physics, The University of Texas, MD . Anderson Cancer Center, Houston, TX 77030, USA.
Starkschall
George
G
Famiglietti
Robin
R
Cox
James
J
Frank
Steven
S
Komaki
Ritsuko
R
Liao
Zhongxing
Z
Stevens
Craig
C
Forster
Kenneth
K
D004999:Amifostine / Q000627:therapeutic use; D002985:Clinical Protocols; D006801:Humans; D008175:Lung Neoplasms / Q000532:radiotherapy; D010347:Patient Care Planning; D011837:Radiation-Protective Agents / Q000627:therapeutic use; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted; D020266:Radiotherapy, Conformal / Q000379:methods*; D011882:Radiotherapy, High-Energy
D011837:Radiation-Protective Agents; D004999:Amifostine